摘要
目的探讨血清LncRNA HOTAIR、HOTTIP、CRNDE和AFAP1-AS1在肺癌骨转移(LCWBM)患者血清中的表达情况,阐明其对LCWBM的诊断价值。方法收集发生骨转移与未发生骨转移肺癌(LCWOBM)患者各38例,调查问卷收集其基本资料,采集其外周静脉血,分离血清。荧光定量PCR技术检测血清HOTAIR、HOTTIP、CRNDE和AFAP1-AS1的表达水平,分析其对LCWBM的诊断价值。结果LCWBM患者血清中HOTAIR的表达水平明显低于LCWOBM患者(P<0.05),血清HOTAIR诊断LCWBM的ROC曲线下面积为0.722,敏感度和特异性分别为70.0%和81.3%;LCWBM患者血清中HOTTIP的表达水平明显高于LCWOBM患者(P<0.05),血清HOTTIP诊断LCWBM的ROC曲线下面积为0.784,敏感度和特异性分别为100%和45.5%。血清HOTAIR、HOTTIP两指标联合诊断LCWBM的ROC曲线下面积为0.818,敏感度和特异性为87.5%和72.7%,阳性预测值和阴性预测值为70.0%和88.9%。结论血清LncRNA HOTAIR和HOTTIP有作为预测肺癌骨转移生物标志物的潜力。
Objective To investigate the expression of lncRNA HOTAIR,HOTAIR,CRNDE and AFAP1-AS1 in lung cancer patients with bone metastasis(LCWBM),and to elucidate the diagnostic value of lncRNAs for LCWBM.Methods Serum was collected from 38 LCWBM patients and 38 lung cancer without bone metastasis(LCWOBM)patients.Questionnaires were used to collect basic information of patients.Fasting peripheral venous blood of patients was collected to separate serum.qRT-PCR was used to measure the expression levels of four serum lncRNAs,and their diagnostic value for LCWBM was analyzed.Results The expression of serum HOTAIR was decreased in LCWBM patients,compared with LCWOBM patients(P<0.05);the AUC of serum HOTAIR diagnosing LCWBM was 0.722(sensitivity was 70.0%,specificity was 81.3%).And the level of serum HOTTIP was significantly increased in LCWBM patients,compared with LCWOBM patients(P<0.05);AUC of serum HOTTIP diagnosing LCWBM was 0.784(sensitivity was 100.0%,specificity was 45.5%).The AUC of serum HOTAIR combined with HOTTIP diagnosing LCWBM was 0.818(sensitivity,specificity,positive predictive value and negative predictive value were 87.5%,72.7%,70.0%and 88.9%,respectively).Conclusion Serum lncRNA HOTAIR and HOTTIP might be potential diagnostic biomarkers for bone metastases in lung cancer patients.
作者
张鹏
高敏
冯斐斐
李梦圆
刘金燕
黄玲玲
ZHANG Peng;GAO Min;FENG Feifei;LI Mengyuan;LIU Jinyan;HUANG Lingling(Department of Bone and Soft Tissue Sarcoma,The Affiliated Cancer Hospital of Zhengzhou University(Henan Cancer Hospital),Zhengzhou 450008,China;College of Public Health,Zhengzhou University,Zhengzhou 450001,China)
出处
《肿瘤防治研究》
CAS
CSCD
2022年第6期593-598,共6页
Cancer Research on Prevention and Treatment
基金
河南省科技攻关项目(162102310319)
河南省医学科技攻关计划联合共建项目(2018020477)
河南省高等学校重点科研项目(20B320042)。